Financhill
Back

Stoke Therapeutics Quote, Financials, Valuation and Earnings

Stoke Therapeutics Price Quote

$15.88
-0.04 (3.42%)
(Updated: September 11, 2024 at 5:21 AM ET)

Stoke Therapeutics Key Stats

Buy
57
Stoke Therapeutics (STOK) is a Buy

Day range:
$14.80 - $15.92
52-week range:
$3.35 - $17.58
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
46.31
P/B ratio:
3.18%

Volume:
322.2K
Avg. volume:
395.3K
1-year change:
199.81%
Market cap:
$772.9M
Revenue:
$8.8M
EPS:
$-2.18

How Much Does Stoke Therapeutics Make?

Is Stoke Therapeutics Growing As A Company?

Data Unavailable

Stoke Therapeutics Stock Price Performance

What Is Stoke Therapeutics 52-Week High & Low?

Stoke Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Stoke Therapeutics?

Is Stoke Therapeutics Cash Flow Positive?

  • What Is STOK Cash Flow From Operations?
    Cash flow from operations (TTM) is -$80M
  • What Is Stoke Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $130.3M
  • What Is Stoke Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$48.9M

Stoke Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    STOK return on invested capital is -57.17%
  • What Is Stoke Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.83%
  • What Is STOK Return On Equity?
    ROE is a measure of profitability and is -57.17%

Stoke Therapeutics Earnings Date & Stock Price

Stoke Therapeutics Competitors

Stoke Therapeutics Dividend Yield

Stoke Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 18.58%
Revenue: 0% 41.57%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 22.14
Upside from Last Price: 39.09%

Major Shareholders

  • How many STOK shares are owned by institutional investors?
    83.3M STOK shares are owned by institutional investors
  • How many STOK shares are owned by insiders?
    510.6K STOK shares are owned by insiders